Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management.

cerebral palsy immune checkpoint inhibitors immune toxicity ipilimumab neurological toxicity nivolumab

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 23 01 2024
accepted: 11 03 2024
medline: 8 4 2024
pubmed: 8 4 2024
entrez: 8 4 2024
Statut: epublish

Résumé

Neurological immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICI) are rare complications of immunotherapy, particularly dreadful for patients and clinical teams. Indeed, neurological irAEs are potentially severe and their diagnosis require prompt recognition and treatment. Additionally, the spectrum of neurological irAEs is broad, affecting either neuromuscular junction, peripheral or central nervous system. Here, we described the case of a 55-year man with metastatic melanoma, facing a brutal right peripheral cerebral palsy after his third ipilimumab/nivolumab infusion. After the case presentation, we reviewed the literature about this rare complication of immunotherapy, and described its diagnosis work-up and clinical management.

Identifiants

pubmed: 38585263
doi: 10.3389/fimmu.2024.1375497
pmc: PMC10995231
doi:

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

1375497

Informations de copyright

Copyright © 2024 Mezni, Corazza, Mari, Coze, Charrier, Chanez, Chretien and Rochigneux.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Essia Mezni (E)

Medical Oncology Department, Paoli-Calmettes Institute, Marseille, France.

Giovanni Corazza (G)

Neurology Department, Assitance Publique Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.
Referral Centre for Neuromuscular Diseases and Amyotrophic Lateral Sclerosis (ALS), Hôpital La Timone, Marseille, France.

Roxane Mari (R)

Medical Oncology Department, Paoli-Calmettes Institute, Marseille, France.

Stephanie Coze (S)

Radiology Department, Assitance Publique Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.

Nathalie Charrier (N)

Nuclear Medicine Department, Paoli-Calmettes Institut, Marseille, France.

Brice Chanez (B)

Medical Oncology Department, Paoli-Calmettes Institute, Marseille, France.

Anne Sophie Chretien (AS)

Team Immunity and Cancer, Centre de Recherche en Canceírologie de Marseille (CRCM), Inserm, U1068, Centre national de la recherche scientifique (CNRS), Unité Mixte de Recherche 7258 (UMR7258), Paoli-Calmettes Institute, Aix-Marseille University, Marseille, France.

Philippe Rochigneux (P)

Medical Oncology Department, Paoli-Calmettes Institute, Marseille, France.
Team Immunity and Cancer, Centre de Recherche en Canceírologie de Marseille (CRCM), Inserm, U1068, Centre national de la recherche scientifique (CNRS), Unité Mixte de Recherche 7258 (UMR7258), Paoli-Calmettes Institute, Aix-Marseille University, Marseille, France.

Classifications MeSH